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Abstract 20 
Effective drug delivery to the lungs by a DPI device requires the air-stream through the device to 21 
have sufficient power to aerosolise the powder.  Furthermore, sufficient turbulence must be induced, 22 
along with particle-wall and particle-particle collisions, in order to de-aggregate small drug particles 23 
from large carrier particles.  As a result, the emitted and the fine particle doses produced by many 24 
commercially available DPI devices tend to be strongly affected by the natural inter-patient 25 
variability of the inhaled air flow.  The Nexthaler® is a multi-dose breath-actuated dry-powder 26 
inhaler with minimum drug delivery-flow rate dependency and incorporating a dose protector. The 27 
actuation mechanism of the dose-protector ensures that the dose is only exposed to the inhaled air 28 
flow if the flow has sufficient power to cause complete aerosolisation.  For this study, a proprietary 29 
lactose placebo powder blend was filled into “transparent “ Nexthalers® to allow application of high-30 
speed imaging and particle image velocimetry (PIV) techniques to successfully interrogate and 31 
reveal details of the powder entrainment and emission processes coupled with characterisation of 32 
the flow environment in the vicinity of the mouthpiece exit.   33 
The study showed that fluidisation of the bulk of the powder occurs very quickly (?20 ms) after 34 
withdrawal of the dose protector followed by powder emission from the device within ~50 ms35 
thereafter.  The bulk of the metered placebo dose was emitted within 100-200 ms.  The visualisation 36 
study also revealed that a very small fraction of powder fines is emitted whilst the dose protector still 37 
covers the dosing cup as the flow rate through the device accelerates.  The PIV results show that 38 
the flow exiting the device is highly turbulent with a rotating flow structure, which forces the particles 39 
to follow internal paths having a high probability of wall impacts, suggesting that the flow 40 
environment inside the Nexthaler® DPI will be very beneficial for carrier-drug de-aggregation. 41 
42 
Keywords: powder fluidization; dry powder inhaler; breath-actuated; optical diagnostics; high-speed 43 
imaging; particle image velocimetry; powder emission  44 
45 
 46 
1.  Introduction 47 
Dry powder inhalers (DPI) deliver therapeutic agents to the lungs and airways in the form of a 48 
powder aerosol. To achieve efficient delivery of these agents to the lungs, perceived wisdom 49 
suggests the aerodynamic particle size should range between 1 and 5 ?m (Laube et al., 2011), 50 
although it is arguable that sub-micron particles are also capable of lung deposition and retention, 51 
(Acerbi et al., 2007, Church et al., 2010, Kuna et al., 2015). Micronised drug powders in these 52 
ranges tend to be very cohesive and, consequently, to ensure flowability during formulation 53 
manufacture, device filling, storage and use, drug particles are presented in the form of aggregates 54 
of micronized drug particles alone or of drug and coarse lactose carrier particles, (Newman and 55 
Busse, 2002).  56 
Most of the DPI devices currently on the market are breath-actuated, single-dose or multi-dose DPIs 57 
(British National Formulary 68, 2014, EMC, 2015, Physician’s Desk Reference, 2015). In these 58 
devices, the powder is aerosolised by the flow of air inhaled by the patient, which obviates the need 59 
for the patient to coordinate actuation/priming of the device and inhalation.  However, as 60 
demonstrated in early work (Clark and Hollingsworth, 1993; Hindle and Byron, 1995; de Boer et al., 61 
1996), this advantage also has a well-known drawback, for many DPI systems, in that the resultant 62 
delivered and fine particle doses vary with the inhalation flow rate, which, in turn, depends on an 63 
individual patient’s lung function and the device resistance.  Staniforth (1995) studied the 64 
dependence of the fraction of a powder dose entrained by an air stream in a simple entrainment 65 
tube with circular cross-section, on flow velocity and the size of carrier particles.  This work showed 66 
that partial fluidisation of the powder dose is initiated at lower air velocities, but complete fluidisation 67 
requires significantly higher velocities.  Furthermore, complete aerosolisation takes place at lower 68 
velocities if the particles are larger.  Clearly, the patient must be able to inhale with sufficient force to 69 
fluidise the powder-dose completely (Laube et al., 2011).  Moreover, in-vitro studies have shown 70 
that the emitted dose and the fine particle fraction of active drug emitted by the device depends on 71 
the inhalation flow rate and its temporal profile (Everhard et al., 1997; Hawsksworth et al., 2000; 72 
Chavan and Dalby, 2002).  73 
Theories of powder fluidisation and de-aggregation (Dunbar et al. 1998, Finlay, 2001) propose that 74 
shear fluidisation is responsible for entrainment of particles in the vicinity of a solid wall immersed in 75 
a high speed boundary layer.  Estimates of the fluid velocity required to initiate particle movement 76 
were made on the basis of a balance between aerodynamic lift and drag forces vs. particle weight 77 
and adhesion forces.  Sweeney and Finlay (2007) gave details of a numerical study of the 78 
aerodynamics of a sphere attached to a wall and immersed in a boundary layer under 79 
hydrodynamic conditions that are representative of practical DPI flows; this work provided 80 
interpolated closed-form relationships for the aerodynamic lift and drag coefficients that are useful 81 
for accurate evaluations of the force balance.  Voss and Finlay (2002) compared particle de-82 
aggregation in air flows with independent control of turbulence levels and mechanical impaction 83 
conditions in a simplified entrainment tube test rig and a Diskhaler®.  Laser-Doppler velocimetry 84 
was used to measure turbulent flow velocities inside both systems.  Their results showed that 85 
turbulence in the air flow is the main variable that affects de-aggregation, an important finding for 86 
subsequent device development.  In separate work, Wang et al. (2004) studied Ventodisk® powder 87 
fluidisation using normally impacting jet flows, as commonly found in commercial DPIs and reported 88 
that the jet velocity, the amount of drug formulation loaded and the geometries of the jet and powder 89 
dosing cup all affect fluidisation.  Powder dispersion and drug de-aggregation were found to be 90 
controlled by a combination of the following mechanisms: shear fluidisation, flow turbulence, jet 91 
energy as well as particle-wall collisions.  Zhou et al. (2010) studied fluidisation of lactose powders 92 
with median particle sizes around 4 and 20 ?m, with and without magnesium stearate in a 93 
Monodose® (RS01 Plastiape) inhaler device. The study highlighted the role of powder bulk 94 
characteristics and the potential of powder surface modification to improve aerosol performance, 95 
reducing emitted drug dose dependence on the inhalation flow rate and improvement in drug de-96 
aggregation.  The theoretical approach developed by Xu et al. (2010) for the study of particle 97 
fluidisation in turbulent air flows within simplified entrainment tubes enabled predictions of drug fine-98 
particle fraction in the resultant aerosol cloud.  Recent work by Xu and Hickey (2013) confirmed that 99 
predictions based on this theory show excellent agreement with the measured trends of fine-particle 100 
fractions as a function of air flow rate in commercial DPIs.  Despite such investigations, for many 101 
widely prescribed products, there remains significant potential for poorly controlled interactions 102 
between the powder and inhaled air stream resulting from natural variations in the patterns of 103 
patients’ inspiration and their different abilities to inhale with sufficient force.  These factors can 104 
potentially lead to variations in the effectiveness of drug therapy delivered by means of dry-powder 105 
inhalers as a consequence of: 106 
(i) incomplete powder fluidisation when a patient is unable to inhale sufficiently forcefully. 107 
(ii) inconsistency of drug release from carrier vehicles due to variations of the strength of the 108 
  inhaled air currents.  109 
The exact details of the mechanism of powder fluidisation and subsequent drug release into the 110 
more complex air stream within commercial DPIs are still not well understood making it difficult to 111 
take a fundamental approach to DPI device design, which, consequently, proceeds largely on an 112 
empirical basis reliant on extensive use of cascade impaction testing (Friebel et al., 2013).  The 113 
challenges associated with sensing and measuring the rapid transient motion of dense particle-114 
laden flows have been insurmountable until fairly recently.  However, powerful optical diagnostic 115 
techniques are now available for imaging and measurements.  One such technique, particle image 116 
velocimetry (PIV), was used by Ngoc et al. (2013) to study details of the flow fields and turbulence 117 
distribution in a de-agglomeration chamber of an idealised DPI.  This yielded a deeper 118 
understanding of the flow mechanisms and geometrical factors controlling device performance.   119 
In this paper we describe the use of optical diagnostics techniques, comprising high speed imaging 120 
coupled with PIV to study powder fluidisation and particle cloud emission from Nexthaler®, a multi-121 
dose, breath-actuated, dry powder inhaler device approved for the delivery of drug powder 122 
formulations for the treatment of Asthma and COPD.    123 
124 
2. Materials and Methods 125 
2.1  “Transparent” Nexthalers 126 
The components of commercial Nexthalers®, (Corradi et al., 2014), are machine or hand 127 
assembled from filled plastic pieces fabricated on multi-cavity tools.  To allow the required internal 128 
optical access for this study, “transparent” versions were hand assembled from un-filled pieces, of 129 
otherwise identical material composition, fabricated using the identical moulding tools and 130 
conditions. For the data presented, two Nexthaler devices were used; one for the imaging testing 131 
(refilled as required) and one for the velocity measurements. The device incorporates a dose 132 
protector, which covers the metered mass of formulation, (dose), released when the device is 133 
primed prior to inhalation.  It is designed to retract only when the suction produced by the inspiratory 134 
effort of the patient reaches the pre-set “trigger” value.  As a consequence, the powder dose can 135 
only be exposed to a powerful inhaled air current, thereby ensuring its complete fluidisation and 136 
efficient dose emission. 137 
138 
 139 
2.2 Inhalation Powder Formulation 140 
The powder reservoirs of part-assembled devices were hand-filled with 1.5 g of a proprietary 141 
lactose-excipient placebo blend, manufactured at commercial scale (Chiesi Farmaceutici, Parma)142 
and the DPI assembly completed. 143 
144 
2.3 Optical Diagnostics Test Rig 145 
2.3.1 Components 146 
The experimental apparatus used for high-speed visualisation and measurement of the particle 147 
velocities within and emerging from a “transparent” Nexthaler® comprises a pneumatic suction 148 
system equipped with rapid response pressure and flow measurement instrumentation and optical 149 
systems.  The apparatus, shown schematically in Figures 1-3, was assembled in-house utilising the 150 
following components. 151 
152 
A.  Vacuum pump – Edwards Speedivac ED660 153 
B.  Control valve – Legris Stainless steel ball valve 154 
C.  20 litre steel vacuum vessel  155 
D.  Sonic Restrictor – made in-house 156 
E.  Flow Control Valve – Legris Stainless steel ball valve 157 
F.  Rapid Switch Solenoid Controlled Ball Valve – Omal SR15 driven with 6 bar pressure 158 
G. Variable Volume Unit – made in-house 159 
H.  Thermal Mass Flow Meter – Sierra 0-200 sl.min-1 Accuracy: 1.0% of full scale   160 
I.  Particle Filter Housing with 1μm Particle Retention Filter – Pall Corporation type A/E 161 
JV, JH  Custom-built adaptors with optical access - PMMA construction with an optical crown glass 162 
window, internal dimensions of 28 x 28 x 60 mm, two variations fitted with a silicone rubber seal 163 
where it meets the Nexthaler® Mouthpiece 164 
K.   Nexthaler® Device 165 
L. Vertical Laser Sheet (see Section 2.3.2) 166 
M. Nikkor 105mm macro lens 167 
N. Photron APX RS High-speed camera 168 
O. Front coated mirror  60 mm x 40 mm  169 
PD, Pu  Pressure Transducers – Kistler 4045A5 (25 mV/bar/mA sensitivity, natural 170 
frequency ≈ 80 kHz) used in conjunction with a National Instruments 6110 series data logger 171 
Q.    Fibre Optic Delivery of Laser Light 172 
Rc, Rs, Cylindrical & Spherical Lenses 173 
174 
INSERT FIGURE 1 HERE 175 
Figure 1: Schematic of Optical Diagnostics Test Rig 176 
177 
2.3.2 Test Rig Pneumatics Design Rationale and Operation 178 
Figure 1 shows the pneumatics assembly within the test rig.  Components A – J were linked by 179 
nylon hoses (ID 8 mm). The Nexthaler® device was positioned in a vertical orientation with suction 180 
applied, via the optical access adaptor J, in the same direction. This arrangement was defined by 181 
the needs of the experiment, but did not affect the operation of the device which is flow-dominated.  182 
Although patients’ inhalation profiles are individual and complex functions of time and inspiration 183 
(Kenyon et al., 1999; Miller et al., 2000), the transient air flow through a device can be more simply 184 
characterised in terms of the peak inhalation flow rate (Qmax), the total inhaled air volume, inhalation 185 
duration and flow rate acceleration, (Everhard et al., 1997; Yakubu et al., 2013).  Furthermore, 186 
many dry-powder inhalers emit the formulation rapidly from the device before completion of the 187 
initial flow acceleration phase of inspiration (Everhard et al., 1997; Burnell et al., 1998; Finlay & 188 
Gehmlich, 2000).  For our purpose of studying the phenomena of metered powder release, 189 
fluidisation and transport to the device mouthpiece, it was considered sufficient to generate 190 
controlled suction (inspiration) profiles up to the peak flow rate (Qmax) and ignore the subsequent 191 
tailing portion of the inspiration cycle, which is unlikely to contribute to the powder dose emission 192 
event.  Air flow profiles selected for investigation with the test rig were set in terms of Qmax (40, 60 & 193 
80 l.min-1) and rise time, trise, (0.3, 0.7 and 1.2 s) between initiation of suction and achievement of 194 
steady state pressure differentials, (PU - PD). These parameters are consistent with the majority of 195 
the in vivo inhalation profiles (peak inspiratory flow and time to peak inspiratory flow) reported for a 196 
cohort of 41 adult asthmatics through Nexthaler®, (Casaro et al., 2014), and also enabled 197 
systematic variations of peak air flow rates and the initial rates of change of air flow with respect to 198 
time. Differential suction pressures across the Nexthaler® device were measured using a Kistler 199 
pressure transducer mounted in the optical adaptor (referencing the ambient pressure before 200 
suction). Simultaneous flow rate data were acquired by means of a thermal mass flow meter. This 201 
information was used to characterise the accelerating flow. Suction was produced by first 202 
evacuating the 20 litre vacuum vessel with the vacuum pump (A) to a pressure below 0.1 kPa and 203 
then isolating it using the ball valve (B). This entrapped vacuum generates the necessary pressure 204 
differentials for suction periods up to 4 seconds without the requirement for a high-flow vacuum 205 
pump. The pneumatic system comprises the following functional components. The interchangeable 206 
orifice sonic flow restrictor, (D), prevents turbulent pressure variations at the device mouthpiece by 207 
maintaining the ratio of downstream to upstream pressure across the restrictor < 0.5 for all flow 208 
conditions. The setting of the flow control valve, (E), allows variation of Qmax from 40 to 80 l.min-1. 209 
The rapid switch on/off solenoid-controlled ball valve, (F), has minimal flow resistance when fully 210 
open. Adjustment of the variable volume unit, (G), enables the rise time, trise, to be set between 0.3 211 
and 1.2 s. The steady-state flow rate Qmax is monitored by the thermal mass flowmeter (H). The 212 
1 μm particle filter, (I), collects fluidised powder and prevents deposition on the surfaces of the mass 213 
flow meter and blockages further downstream.   214 
The 20 l volume of the vacuum vessel was sufficiently large to maintain a pressure ratio of 0.5 215 
across the sonic flow restrictor and ensure test durations between 0 and 4 seconds at the chosen 216 
maximum value of flow rate.  The pressure transducer, (PU) mounted on the surface of the laser 217 
illumination box measures the suction pressure at the Nexthaler® mouthpiece.   218 
219 
2.3.3 Test Rig Optics for Imaging  Events Within Nexthaler® 220 
High-speed imaging of the functionality of the dose protector mechanism and powder entrainment 221 
from the dosing cup into the air stream was carried out by examining the region inside the device 222 
where the metered dose of formulation is initially entrained by the air flow.  A high-speed camera (N) 223 
was used in conjunction with a copper-vapour laser light source (Type LS20-10, Oxford Lasers, 224 
Oxford, UK). The laser light was directed to the image area by fibre-optic transmission as shown 225 
schematically in Figures 2a & b. Light pulses of 25 ns duration, were synchronized with the camera 226 
recording at 10,000 frames.s-1 at a  resolution set to 512 by 512 pixels, equivalent to an imaging 227 
area approximately 5 mm by 5 mm.  The imaging configuration utilised a 105 mm Nikkor macro-lens 228 
with an aperture setting of f11 resulting in a pixel resolution limit of approximately 10 μm. 229 
230 
INSERT FIGURE 2 HERE 231 
Figure 2.  Schematic of Optical Equipment Set-up for Imaging Formulation Entrainment from 232 
Nexthaler®  Metering Cup.  (a), Side view,  (b),  Top view 233 
234 
2.3.4 Particle Plume Imaging & Flow Field Velocimetry at Nexthaler® Mouthpiece Exit 235 
High-speed imaging of the particle plume at the exit of the device mouthpiece to investigate its 236 
temporal and spatial structure and two-dimensional high-speed velocity measurement of the ex-237 
mouthpiece flow field using particle image velocimetry (PIV), were carried out using the 238 
experimental arrangement, shown schematically in Figures 3a-b.  239 
240 
INSERT FIGURE 3 HERE   241 
242 
Figure 3: Schematic of Optical Equipment Set-up used for Nexthaler® Ex-mouthpiece Plume 243 
Imaging and Particle Image Velocimetry Measurements.  (a), Side view, (b), Top view 244 
245 
Here, the copper-vapour laser was replaced by a Pegasus dual-cavity neodymium-doped yttrium-246 
lithium fluoride laser, Nd:YLF, (New-wave Research Inc. Fremont CA, USA), as the light source. 247 
This laser enabled illumination using either a single cavity, producing an even pulse separation time 248 
for use in the imaging work, or from both cavities, allowing the separation time between each cavity 249 
to be adjusted for the velocity measurement work.  The light from the laser for the ex-mouthpiece 250 
work was formed into a light sheet using a spherical-cylindrical lens combination. The light sheet 251 
was directed so that it intersected the exit-plume from the device through the centre-line of the 252 
orifice, in-line with the flow direction. The high-speed imaging of the plume was carried out at a 253 
camera speed of 3000 frames.s-1 with a resolution of 1024 by 1024 pixels providing an imaging area 254 
22 x 22 mm and pixel resolution of approximately 22 μm. This resolution limit is significantly larger 255 
than the smallest particles in the flow; however, due to diffraction small particles appear much larger 256 
and cover more than one pixel in the image. 257 
In order to investigate the temporal development of the air flow through the Nexthaler® DPI, particle 258 
image velocimetry was applied to the region of the flow near the exit of the mouthpiece. For these 259 
tests, the device was primed prior to suction but no powder was present. The particles used to trace 260 
the air flow, and thus provide the basis for velocity quantification, were olive oil droplets nominally 261 
1 μm diameter, introduced into the air surrounding the Nexthaler® device via a six-jet atomiser 262 
(model 9306A TSI Instruments UK),  and drawn through the device during the suction event. Olive 263 
oil particles were selected for their light-scattering properties and ability to enable accurate tracking 264 
of the local air-motion through the device even under highly turbulent conditions. The recorded 265 
particle images were analysed using DaVis software (LaVision GmbH) to calculate the flow-field 266 
velocity vectors.   267 
PIV measurements utilised the same equipment set-up, but with the triggering of the laser and 268 
camera altered to create pairs of images. Each image pair had a short and controllable time 269 
separation (2-8 μs) between the first and second image, enabling calculation of particle velocity 270 
from their spatial displacement. Recording of the particle images was carried out at either 1000 or 271 
2000 frames.s-1, providing velocity`measurements at either 500 or 1000 vector fields per second, 272 
depending on the duration of the rise-time being examined. 273 
 274 
3.   Results and Discussion  275 
3.1   Differential (Suction) Pressure Time Profiles 276 
Figure 4 shows the differential pressure-time profiles recorded for eight flow rate, (Qmax) – rise time, 277 
(trise) combinations achieving steady state pressure differential. Due to limitations imposed by the 278 
design of the variable volume unit in the suction system, it was not possible to produce a dataset for 279 
a 0.3 s rise time with a 40 l.min-1 maximum flow rate. The profiles in the upper panels, (ai, aii, aiii), 280 
were obtained using an unfilled Nexhaler® device; those in the lower panels, (bi, bii, biii), were 281 
obtained using a filled Nexthaler® with the metering cup primed by opening the device cover, 282 
(Corradi et al., 2014).  The shapes of the eight profiles in Figure 4 differ from those of Chavan & 283 
Dalby (2002), which show linear flow-time relationships during the flow acceleration phase until the 284 
steady state is achieved at Qmax.  Such a relationship between flow rate and time is easy to describe 285 
mathematically, but involves a discontinuity in the flow acceleration at the changeover between the 286 
initial phase when the flow ramps up and the constant steady-state flow.  Whilst a linear ramp profile 287 
may be suitable for quality assurance testing, it is well known that human inhalation profiles vary in 288 
a quasi-parabolic manner reaching a maximum before tailing. 289 
290 
INSERT FIGURE 4 HERE 291 
292 
Figure 4.: Effect of Variation in flow rate maximum and rise time on suction pressure-time profiles 293 
though Nexthaler® ,  (a) without powder loading but with metering cup primed,  (b) with 294 
powder loading and metering cup primed. (green, red, blue traces; QMAX = 40, 60, 80 295 
l.min-1 respectively; vertical broken black lines delineate rise time set.).296 
297 
In the present system, the initial portion of the profile is similar for each flow rate for a given rise 298 
time. Thereafter the differential pressure traces curve towards the steady state plateau.  The theory 299 
of pneumatic circuits and transmission lines shows that this behaviour can be understood in terms 300 
of the inertance, capacitance and resistance of the test rig’s circuit components and its fluid content.  301 
The traces confirm that independent variation of the peak flow rate Qmax and rise time of the suction 302 
profile has been achieved (i.e. the peak flow rate can be varied while maintaining a constant rise 303 
time), allowing a range of different flow profiles to be achieved. 304 
Figures 4 (b) i–iii show that when the Nexthaler® device is filled and primed, and therefore with the 305 
dose-protector ready to be triggered by the breath-actuated mechanism on actuation, the resultant 306 
pressure-differential profiles through the device differ slightly from those obtained with primed but 307 
un-loaded devices, (Figures 4 (a) i-iii). The appearance of discontinuities (arrowed), indicates that a 308 
change in the rate of change of pressure differential is induced by the resultant particle entrainment.  309 
 310 
3.2  Dose protector functionality and powder fluidisation  311 
Figure 5 presents high-speed images of the functionality of the dose protector mechanism and the 312 
powder entrainment.  The dosing (metering) cup shows as a circular region inside the bright grey 313 
image of the bottom of the device, as seen through the circular mouthpiece orifice.  The powder 314 
dose is initially located in the centre of the dosing cup, where it shows as a white, granular region.  315 
Under the test conditions shown, (Qmax  60 l.min -1, 0.3 second rise time), the dose protector covers 316 
the powder dose until 40 ms after the initiation of suction.  Thereafter, the suction pressure 317 
differential inside the Nexthaler® has built up sufficiently to trigger the breath-actuated mechanism, 318 
which then displaces the dose protector to expose the metered powder to the air flow in the device’s 319 
swirl-chamber below the mouthpiece.  The powder bed starts to rotate immediately, under the 320 
influence of the developing vortex flow in the vicinity of the dosing cup.  The bulk of the powder 321 
dose is rapidly fluidised during the first phase of the interaction, which has a duration of around 20 322 
ms after the dose protector is removed.  A small proportion of the particles remains deeper inside 323 
the dosing cup at this stage.  This region is less exposed to the air flow and this powder remnant is, 324 
therefore, fluidised much more gradually.   325 
 326 
INSERT FIGURE 5 HERE 327 
 328 
Figure 5: Images of dosing (metering) cup region showing powder fluidisation and dose protector  329 
                        functionality.  (Qmax  60 l.min-1, rise time 0.3 s)  330 
 331 
Particle fluidisation during this second phase appears to be stochastic.  The aerodynamic forces are 332 
insufficient to pick up the large carrier particles, but the forces are fluctuating as a consequence of 333 
the high turbulence levels induced in the swirl chamber.  Occasionally one or two particles are 334 
forced to move up towards the top edge of the dosing cup where they can be entrained by the flow 335 
and transported upwards via the swirl chamber to the mouthpiece.  Under the prevailing 336 
experimental conditions, Figure 5 shows that the dosing cup is completely empty approximately 300 337 
ms after the start of the flow. 338 
339 
3.3 Ex-mouthpiece aerosol plume - imaging 340 
The imaging work carried out in section 3.2 has shown that after entrainment into the air flow, the 341 
powder is rapidly transported through the swirl chamber into the outlet tube towards the device 342 
mouthpiece. Within the swirl chamber high levels of swirl are induced by the internal flow passage 343 
geometry of the Nexthaler®.  The air, and hence the particles, are expected to follow spiral paths 344 
with a large circumferential velocity component superposed on the upward axial velocity component 345 
towards the mouthpiece.  The density of the lactose and drug solids is much higher than the air 346 
density, so the aerosol plume will be most dense near the surrounding walls, as can be seen in the 347 
image displayed in Figure 6.  The large carrier particles experience a more pronounced outward 348 
displacement, whereas the fines are more uniformly distributed throughout the aerosol.   349 
A typical single frame image of the emitted aerosolised particles, illuminated by the laser sheet 350 
positioned across the centreline of the mouthpiece, is shown in Figure 6.  For clarity, this image and 351 
Figure 7 have been inverted, to show the particles in the light sheet as dark regions on a light 352 
background.  The general appearance of the cloud suggests that the flow is highly agitated and 353 
turbulent, as confirmed by examination of the complete video.  The larger particles in the placebo 354 
blend experience a more pronounced outward displacement whereas fines are more uniformly 355 
distributed.  This is to be expected, since the design of the internal flow passage geometry of 356 
Nexthaler® induces a spiral path with a large circumferential velocity component superimposed on 357 
the upward axial velocity component to the air drawn through the device by the inhalation 358 
manoeuvre, which is transmitted to the fluidised particles.  The larger the particles, the greater the 359 
unit mass and the greater the centrifugal force imposed. 360 
 361 
INSERT FIGURE 6 HERE 362 
 363 
Figure 6:  Typical Single Frame from High Speed Video Capture of Powder Emission from 364 
                Nexthaler®: (Suction Conditions; Qmax =  60 l.min-1, Rise Time = 0.3 s, Image captured at 365 
0.062 s) 366 
 367 
To characterise the temporal release of the powder from the device mouthpiece, the pixel intensities 368 
within a defined rectangle across the centre of the device mouthpiece, (Figure 6), were summed for 369 
each frame, (∑IPx).  The individual ∑IPX values for a given frame were then normalised against the 370 
maximum value obtained in the entire ensemble of frames in the video from the start to the end of 371 
suction pertaining to that single dose powder discharge from the Nexthaler® unit.  Plotting the 372 
normalised intensities against time, (Figure 7) thus provides a quantitative description of the powder 373 
emission kinetics.  Normalising the summed intensities in this manner allows quantitative 374 
comparison of the effects of Qmax and rise time on the powder emission kinetics by eliminating the 375 
influences of intra-device variations of unit dose metering and temporal variation in laser pulse 376 
energy.   377 
Figure 7a compares the pressure differential (pressure drop, ΔP), generated across the Nexthaler® 378 
with the normalised intensity profiles of powder emission during the air flow acceleration phase of 379 
an event over a rise time of 0.3 s resulting in a steady-state flow rate, (Qmax),  of 60 l.min-1.  Figure 380 
7b presents a selection of (inverted) particle images captured between 30 - 130 ms after 381 
commencement of flow, with the corresponding acquisition time indicated on each frame and its 382 
location on the abscissa of Figure 7a.  The normalised intensity profiles suggest that powder 383 
emission takes place in four phases characterised by: 384 
(i) a small peak (A), normalised intensity ~0.2 around 40 ms,  385 
(ii) a large peak (B), normalised intensity maximum 1.0 around 60 - 70 ms, which is associated 386 
with most of the powder emission, 387 
(iii) a second small peak (C), normalised intensity maximum ~ 0.3 around 80 ms,  followed by,  388 
(iv)   a slow decline in normalised intensity, (D), over 90 – 300 ms with some minor spikes 389 
commensurate with the emission of small bursts of fine particles and a few larger 390 
aggregates, (see Figure 7b, e.g. Frame 642).  391 
Imaging of the dosing cup region, (see section 3.2 figure 5), showed that the bulk of the powder 392 
entrainment takes place between 40 and 60 ms.  The time required to transport the powder from the 393 
dosing cup to the mouthpiece exit explains the delay in appearance of the large intensity peak B, 394 
(Figure 7), at 60-70 ms.  The pressure differential across the Nexthaler®, (Figure 7a), shows a 395 
discontinuity coinciding with the large intensity peak B; equivalent discontinuities for powder-filled 396 
devices are also shown in figures 4b(i –iii).  These can be attributed to the substantial amounts of 397 
flow energy required to lift the particles from the dosing cup to the mouthpiece and the increased 398 
energy dissipation associated turbulent multi-phase flows.  The particle intensity images, (Figure 399 
7b), also show that  peak C, around 80 ms, is linked with the emission of large particles, or 400 
aggregates which are heavier and will therefore be held up inside the device for a longer period of 401 
time than the finer material.  Finally, it should be noted that a small quantity of finer particles is 402 
visible in the images taken at 30 and 40 ms, times when the dose protector still covers the powder 403 
dose.  Careful inspection of high-speed images of the dosing cup region reveals that some air flows 404 
through a narrow gap created by a small uplift of the dose protector due to the build-up of suction in 405 
this region.  This air flow succeeds in dislodging some of the fine material and initiating premature 406 
release.  However, as evidenced by the normalised intensity profile peak areas, (A relative to B+C), 407 
the total amount of this premature emission is very small compared with the release of the majority 408 
of the powder dose.  409 
410 
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413 
To examine the effect of the flow conditions on powder dose emission, the temporal behaviour of 414 
the normalised intensity profiles was compared across all the test conditions used in this study. 415 
Figures 8a-c show the profiles with rise time of 0.3, 0.7 and 1.2 s, respectively.  All three plots show 416 
the time to achieve peak value, (1.0), of normalised-intensity, (tmax), increases with increase in rise 417 
time, but decreases with increase in Qmax, confirming that flow rate acceleration controls powder 418 
emission rate.  The width of the main intensity peak, measured from the point of rapid increase in 419 
intensity gradient between peaks A and B to the point of inflection between peaks B and C, 420 
increases from about 15 ms to 25 ms as the rise time increases from 0.3 s to 1.2 s. However, the 421 
peak width changes little with flow rate, i.e. for the 1.2 s rise time case, the peaks are all between 23 422 
and 25 ms.423 
The early, small peak (i.e. Peak A in Figure 7) occurs 40-50 ms after the suction is switched on for 424 
all test conditions, before movement of the dose protector was observed in the high-speed images. 425 
As noted earlier, the small quantity of fines emission at this stage will occur as soon as a narrow 426 
flow path underneath the dose protector admits sufficient air to pick up fines from the powder dose. 427 
However, the intensity data demonstrates the magnitude of this early peak diminishes with 428 
increasing rise time. 429 
Comparison of the pressure and image-intensity traces shown in figure 7 clearly demonstrates that 430 
the small discontinuity found in the differential-pressure trace coincides with the start of the large 431 
peak in normalised plume-intensity (peak B).  This coincidence is also found in all of the traces 432 
detailed in figures 4 and 8, which supports the view that the pressure discontinuities are associated 433 
with the release of the powder-dose into the flow, not the initiation of dose protector movement. The 434 
delay in the dose-protector movement relative to the start of suction, and hence dose-release, is 435 
dependent on the suction profile and as such varies with both max flow-rate and rise-time.  The 436 
design of the Nexthaler® DPI is such that the dose protector should withdraw when a pre-set 437 
suction of 2 kPa below ambient is reached; comparison of event timings in Figures 4, 5 and 7 shows 438 
that the dose is consistently emitted very shortly after sufficient suction occurs to move the dose 439 
protector.  Figure 4 suggests that, for cases where the peak flow rate is 40 l.min-1, the actual trigger 440 
point of the dose protector is slightly below 2 kPa.  This pressure differential is very close to the limit 441 
of device actuation, which explains why the time from the start of the event flow to the main 442 
normalised intensity peak (shown in figure 8) is much longer than at peak flow rates of 60 and 443 
80 l.min-1.  Achieving a high peak flow rate or a short rise time, on the other hand, requires a large 444 
rate of change of pressure.  Inertia of the dose protector and the powder dose will tend to resist 445 
rapid movements somewhat, consequently suction pressures just above 2 kPa are needed to 446 
achieve dose protector movement and powder release at 60 and 80 l.min-1 flow rates and shorter 447 
rise-time (also see Figure 4).  448 
 449 
 450 
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 452 
Figure 8 – Normalised intensity profiles as function of time for flow conditions: peak flow rate 40 453 
l.min-1 (green traces), 60 l.min-1 (red traces) and 80 l.min-1 (Blue traces).  Rise time: (a) 0.3 s, (b) 0.7 454 
s, (c) 1.2 s  455 
 456 
457 
3.4 Ex-mouthpiece aerosol plume -  Particle image velocimetry   458 
Axial and radial velocity components were measured across a plane perpendicular to the device 459 
exit, along the centreline of the mouthpiece. The measurement region is 20 mm x 20 mm in size, 460 
with single vectors calculated over interrogation regions approximately 0.6 mm x 0.6 mm; 50% 461 
overlap of the interrogation regions provided a vector spacing of 0.3 mm across the field.  An 462 
example of a typical vector field is shown in Figure 9 for the flow conditions Qmax 60 l.min-1, rise time, 463 
0.3 s; the magnitude of the flow velocity is indicated by means of the colour scale. The maximum 464 
velocity of 40 m.s-1 is coloured white.and appears around radius ?5 mm just outside the 465 
mouthpiece.   466 
A slight asymmetry is evident with somewhat larger region of high velocity on the right hand side of 467 
the velocity field images (see figure 10b).  If, as surmised earlier, the air follows spiral paths inside 468 
the device and develops concentrated regions of high-speed flow at the periphery, this accounts for 469 
the reverse flow in evidence around the centreline of the mouthpiece exit, (see Figure 9 near the red 470 
line at radius zero).  This is a well-known secondary flow pattern at high swirl levels, which 471 
generates high shear in the internal flow passages.  After exiting the mouthpiece, the unbalanced 472 
centrifugal force on the rotating flow causes the fastest fluid to move radially outwards.  The flow 473 
interacts with the stationary surroundings, which generates additional shear stress on the external 474 
flow, which in turn causes turbulent eddies, several of which are clearly visible in Figure 9.   475 
476 
477 
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479 
Figure 9 – Typical PIV vector field with analysis line position, Q max = 60 l.min-1 trise = 0.3 s, 0.23 s 480 
after start of suction (arrows indicate 2D direction of flow) 481 
482 
 483 
Quantitative information was extracted from the 2D vector flow fields by calculating a mean axial 484 
velocity component (V ) as follows:  485 
 ? ??
i
Lii AAVV , 486 
where iV = velocity at location i,  ?Ai =  area of the image plane used in the velocity measurement at 487 
location i,  AL = total area used for the velocity measurements that intersect the analysis line;  points 488 
i are spaced uniformly along a line parallel to the device exit orifice (red line in Figure 9).   489 
 490 
Since turbulent eddies cause large instantaneous variations in the local axial velocity, smoothed V  491 
values are reported, to produce more meaningful data.  These were computed using a shifting time 492 
average over ten vector fields, corresponding to an averaging time of 10 ms.   493 
494 
Figure 10a shows smoothed mean axial velocity-time profiles obtained for Nexthaler® during the 495 
flow acceleration phase with the same flow conditions as the high-speed imaging tests reported 496 
above (section 3.3, Figure 7) i.e. steady-state air flow rate conditions Qmax, 60 l.min-1, rise time 0.3s 497 
along with the recorded differential pressure.  It should be noted that the averaging of these axial 498 
velocity components along the analysis line (see figure 9) does not exactly represent the mean axial 499 
flow velocity at the device-exit since the analysis line was extended beyond the 8 mm diameter 500 
mouthpiece (figure 9) to off-set the turbulent and spreading nature of the post-orifice flow and only 501 
represents the narrow section of flow illuminated by the laser sheet.  However, the increase of the 502 
mean velocity is found to correlate well with the decrease of the measured pressure differential, 503 
suggesting that the post-processed average axial velocity across the sample line (shown in figure 504 
10) is a good indication of the general changes of the flow rate of the air drawn through the device 505 
as a function of time.   506 
Figure 10b presents a selection of PIV velocity vector fields with the corresponding time indicated 507 
on each frame as well as the location on the time axis.  The velocity scale is the same for all 508 
images, white corresponding to 40 m.s-1 and dark blue to zero m.s-1, respectively.  The maximum 509 
value is clearly lower in the first image (25ms) when flow rate is still increasing, but otherwise the 510 
PIV images show the same flow features noted earlier for Figure 9 with flow asymmetry toward the 511 
right of the images, possibly induced by the internal flow paths within the Nexthaler® device. 512 
513 
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4.  Conclusions 517 
In this study, we have successfully applied optical diagnostics to characterise various aspects of the 518 
Nexthaler® DPI and demonstrated how detailed information about the device functionality and 519 
powder dose emission can be obtained by means of these techniques.   520 
Results from the study have shown that fluidisation of the bulk of the powder occurred shortly after 521 
the withdrawal of the dose protector.  Powder was found to arrive at the mouthpiece exit after a 522 
short delay due to transport of the powder from the dosing cup to the mouthpiece exit by the air 523 
stream.  The powder dose is mainly emitted in a short burst, which occurs after the withdrawal of the 524 
dose protector, with a duration between 15 and 40 ms, dependent upon Qmax and rise time (flow rate 525 
acceleration).  Thereafter there is an emission of larger particles with residual fine material for a 526 
further 100 - 150 ms.  Most of the powder dose has been aerosolised within 100ms of flow initiation. 527 
The visualisation study also revealed that a small fraction of the fines is emitted whilst the dose 528 
protector still covers the dosing cup.   529 
High-speed imaging studies have shown that a highly turbulent, rotating flow is created in the 530 
internal passages of Nexthaler®. These high swirl levels generate a highly sheared, turbulent flow 531 
inside the device, which interacts with the stationary surrounding air just outside the mouthpiece 532 
generating additional turbulence within the emitted plume.  Moreover, the centrifugal force flings the 533 
larger carrier particles radially outwards towards the walls of the internal passages increasing the 534 
probability of wall impacts.  535 
536 
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